VivaCell granted United States Patent for VCE-003 pharmaceutical use in PPARγ-related diseases


VivaCell Biotechnology today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the application number No. 13/636,214 entitled “Cannabinoid Quinone Derivatives”. This patent specifically covers VCE-003 pharmaceutical use in PPARγ-related diseases such as inflammatory ones. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application.

VCE-003 is a cannabigerol semi-synthetic derivative which is being developed as a disease-modifying drug for the treatment of Multiple Sclerosis (MS). Accordingly, the therapeutic potential of VCE-003 has been confirmed in EAE and TMVE mice models of MS. VCE-003 attenuated MS clinical scores, accompanied by decreased microglial activation, myelin sheets structure preservation and reduced axonal damage.

VivaCell’s intellectual property portfolio includes the protection for this patent along Europe, Canada and Japan. Additionally, the patent portfolio includes the application for several VCE-003 derivatives that improve VCE-003 efficacy, diminish the electrophilic profile and optimize the chemical synthesis. The oral bioavailability of these cannabigerol derivatives is assured by Aphios’s drug delivery technologies.

Developed with DoPlanning